The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update.
This is the second revision and update of the international guideline for the diagnosis and management of HAE, which was developed by the World Allergy Organization (WAO) in collaboration with the European Academy of Allergy and Clinical Immunology (EAACI). This revised and updated WAO/EAACI guideline on the diagnosis and management of HAE differs from previous versions and other guidelines, consensus reports, and position papers in that it builds on the most recently published evidence on HAE and the expertise and experience of a global panel of experts.
Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up-to-date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1 inhibitor (type 1) and HAE with dysfunctional C1 inhibitor (type 2), by providing guidance on common and important clinical issues, such as: (1) How should HAE be diagnosed? (2) When should HAE patients receive prophylactic on top of on-demand treatment and what treatments should be used? (3) What are the goals of treatment? (4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast-feeding women? and (5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients.
Download the international WAO/EAACI guideline for the management of hereditary angioedema here
Registration for expert panel and author group now open
Join the expert panel and author group for the revision and update of the international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of angioedema.
In order to register, please click the button below. You will be asked to fill out a form, upload a Letter of Endorsement and state your Conflict of Interest.
Please note that regarding the Letter of Endorsement, it needs to show that you are a delegate of an international, national or regional scientific or medical society. This letter should state that you are a representative and delegate of the society and that your participation secures endorsement of the update and revision of the guideline by the society you represent.
The wording should be something like this:
“We (name of society) confirm that (your name) has been appointed as our delegate for the revision and update of the international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of angioedema”
Simply sending e.g. a membership confirmation is not sufficient.
You may use this form: Form_Delegate_of_Scientific_Society_Guidelines_Angioedema
Regarding the Conflict of Interest, please note that in the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to your participation in the expert panel of the update and revision of the angioedema guideline. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the angioedema guideline. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. All declarations of potential or actual conflicts of interest, whether due to a financial or other relationship, must be provided to GA²LEN upon submission of the application. Declarations must include whether any fee, honorarium, or arrangement for re- imbursement of expenses in relation to the update and revision of the angioedema guideline has been provided.
If you have any questions, please reach out to Emilia Zimmermann at emilia.zimmermannATga2len.berlin